BMSEHA15
Published online 16 July 2009
Haematologica, Vol 94, Issue 12, 1767-1770 doi:10.3324/haematol.2009.010900
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raponi, S.
Right arrow Articles by Guarini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raponi, S.
Right arrow Articles by Guarini, A.

Acute lymphoblastic leukemia

An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia

Sara Raponi1, Maria Stefania De Propris1, Hobert Wai2, Stefania Intoppa1, Loredana Elia1, Daniela Diverio1, Antonella Vitale1, Robin Foà1, Anna Guarini1

1 Division of Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome, Italy
2 BD Biosciences, San Jose, CA, USA

Correspondence: Robin Foà, Division of Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome, Via Benevento, 6, 00161 Rome, Italy. E-mail: rfoa{at}bce.uniroma1.it

Tyrosine kinase inhibitors have profoundly modified the treatment and prognosis of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. A rapid and accurate detection of the BCR-ABL fusion protein is paramount today for an optimal management of Ph+ acute lymphoblastic leukemia. We have utilized a recently described and commercialized immunoassay that identifies qualitatively the presence of the BCR-ABL protein in leukemic cell lysates. The BCR-ABL fusion protein is captured and detected by a cytometric bead assay and analyzed by flow cytometry. The assay was applied to 101 primary patient samples (94 acute leukemias and 7 chronic myeloid leukemia blast crisis) and the results of the immunoassay were concordant with those obtained by conventional molecular techniques. The method proved reliable, reproducible, of simple execution and it was successfully completed within four hours. This flow cytometric immunoassay has important implications for perfecting the management of Ph+ acute lymphoblastic leukemia patients worldwide.

Key words: flow cytometric diagnosis, acute lymphoblastic leukemia.




This article has been cited by other articles:


Home page
 haematolHome page
J. Cools and P. Vandenberghe
New flow cytometry in hematologic malignancies
Haematologica, December 1, 2009; 94(12): 1639 - 1641.
[Full Text] [PDF]